← Leaderboards
Margaret Rick
Clinical Center
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Clinical Center
Same institution · by research overlap
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchPatient Oriented ResearchProtein Structure FunctionVon Willebrand FactorThrombocytopenic PurpuraDiagnosis Design /EvaluationIntermolecular InteractionPolymerase Chain ReactionPlateletsMolecular PathologyFamily GeneticsVon Willebrand'S DiseaseNucleic Acid SequenceMolecular CloningHuman Genetic Material TagBlood ProteinsCoagulation Factor ViiiGenetic SusceptibilityProteolysisBlood Disorder DiagnosisGene MutationDisease /Disorder Proneness /RiskMolecular Site
Grant awards (29)
Identification Of Proteolytic Activity For Von Willebran$0
Z01 · FY2006 · CL · contact PI
Platelet Function In Patients Treated With SSRIs$0
Z01 · FY2005 · CL
Identification Of Proteolysis For Von Willebrand Factor$0
Z01 · FY2005 · CL
Identification Of Molecular Defects In Patients With Von$0
Z01 · FY2004 · CL
Platelet Function In Patients Treated With SSRI Vs. Non-$0
Z01 · FY2004 · CL
Identification Of Proteolytic Activity For Von Willebran$0
Z01 · FY2004 · CL
Platelet-associated Antibodies In Patients With Autoimmu$0
Z01 · FY2004 · CL
Platelet-associated Antibodies In Patients With Autoimmu$0
Z01 · FY2003 · CL
Platelet Function In Patients Treated With SSRI Vs. Non-$0
Z01 · FY2003 · CL
Identification Of Proteolytic Activity For Von Willebran$0
Z01 · FY2003 · CL
Identification Of Molecular Defects In Patients With Von$0
Z01 · FY2003 · CL
Markers Of Disease Activity In Idiopathic Inflammatory M$0
Z01 · FY2002 · CL
Identification Of Molecular Defects In Patients With Von$0
Z01 · FY2002 · CL
Platelet-associated Antibodies In Patients With Autoimmu$0
Z01 · FY2002 · CL
Identification Of Proteolytic Activity For Von Willebran$0
Z01 · FY2002 · CL
Platelet Function In Patients Treated With SSRI Vs. Non-$0
Z01 · FY2002 · CL
Proteolytic Activity For Von Willebrand Factor$0
Z01 · FY2001 · CL
Genetic Abnormalities In Patients With Thrombophilia$0
Z01 · FY2001 · CL
Platelet Function In Patients Treated With Ssri Vs. Non-$0
Z01 · FY2001 · CL
Assay For Autoimmune Thrombocytopenic Purpu$0
Z01 · FY2001 · CL
Biomarkers In Idiopathic Inflammatory Myopathy$0
Z01 · FY2001 · CL
Molecular Defects In Von Willebrand Disease$0
Z01 · FY2001 · CL
Platelet-associated Antibodies in Patients with Autoimmune Thrombocytopenic Purp$0
Z01 · FY2000 · CL
Genetic Defect in Bernard Soulier Syndrome$0
Z01 · FY2000 · CL
Markers of Disease Activity in Idiopathic Inflammatory Myopathy$0
Z01 · FY2000 · CL
Identification of BCR-ABL in Patients With Chronic Myelogenous Leukemia$0
Z01 · FY2000 · CL
Identification of Proteolytic Activity for Von Willebrand Factor$0
Z01 · FY2000 · CL
Genetic Abnormalities in Patients with Thrombophilia$0
Z01 · FY2000 · CL
Identification of Molecular Defects in Patients with von Willebrand$0
Z01 · FY2000 · CL